Fatty Liver Linked to Reduced Frequency of Ocular Complications in T2DM — Oak Academic Publishing
Research ArticleOpen AccessGoogle Scholar indexed
Fatty Liver Linked to Reduced Frequency of Ocular Complications in T2DM
Service d’Endocrinologie & Diabétologie, Faculté des Sciences de la Santé, Cotonou, Bénin
,
Division of Cardiology, Cliniques Universitaires St-Luc and Pôle de Recherche Cardiovasculaire, Institut de Recherche Expérimentale et Clinique (IREC), Université catholique de Louvain, Brussels, Belgium
,
Departmental Hospital and University Centre, Service de Médecine interne-Endocrinologie, CHUD/OP Porto-Novo, Université d’Abomey-Calavi, Abomey-Calavi, Bénin
,
Service de Maladies Métaboliques et Endocriniennes, Centre Hospitalier et Universitaire de Brazzaville, Brazzaville, Congo
,
Division of Cardiology, Cliniques Universitaires St-Luc and Pôle de Recherche Cardiovasculaire, Institut de Recherche Expérimentale et Clinique (IREC), Université catholique de Louvain, Brussels, Belgium
,
Division of Endocrinology & Nutrition, Cliniques universitaires St-Luc and Institut de Recherche Expérimentale et Clinique (IREC), Université catholique de Louvain, Brussels, Belgium
1 Service d’Endocrinologie & Diabétologie, Faculté des Sciences de la Santé, Cotonou, Bénin
2 Division of Cardiology, Cliniques Universitaires St-Luc and Pôle de Recherche Cardiovasculaire, Institut de Recherche Expérimentale et Clinique (IREC), Université catholique de Louvain, Brussels, Belgium
3 Departmental Hospital and University Centre, Service de Médecine interne-Endocrinologie, CHUD/OP Porto-Novo, Université d’Abomey-Calavi, Abomey-Calavi, Bénin
4 Service de Maladies Métaboliques et Endocriniennes, Centre Hospitalier et Universitaire de Brazzaville, Brazzaville, Congo
5 Division of Cardiology, Cliniques Universitaires St-Luc and Pôle de Recherche Cardiovasculaire, Institut de Recherche Expérimentale et Clinique (IREC), Université catholique de Louvain, Brussels, Belgium
6 Division of Endocrinology & Nutrition, Cliniques universitaires St-Luc and Institut de Recherche Expérimentale et Clinique (IREC), Université catholique de Louvain, Brussels, Belgium
Purpose: Non-alcoholic fatty liver (NAFL) is comorbid to obesity, metabolic syndrome and type 2 diabetes mellitus (T2DM). It is unclear whether NAFLD constitutes a direct risk factor for macrovascular disease in T2DM. This study aimed at revisiting the cardiometabolic traits linked to NADL and micro-/ macrovascular complications in a biethnic Caucasian and African cohort. Methods: Cross-sectional analysis of 568 of T2DM patients (515 Caucasians; 53 Africans) in whom the presence of NAFL was identified by ultrasonography and the cardiometabolic phenotype was exhaustively characterized, including carbohydrate homeostasis, comprehensive lipidogram including Lp(a), cumulative exposure to hyperglycemia, and prevalent micro/macrovascular complications. Results: FL was present in 73% of Caucasians and 36% of Africans (p < 0.0001). FL+ were more obese, more atherogenic dyslipidemic (Caucasians) and had lower lipoprotein(a) (Africans). All-cause macroangiopathy, ischemic heart disease or stroke did not significantly differ between FL+ and FL − in both groups. A marked reduction in diabetic retinopathy (DR), ocular hypertonia and cataracts were found in FL+ of the two ethnicities. In FL+ Caucasians, relative risk of DR was − 38%, cataracts − 35%, and ocular hypertonia − 42%. In FL+ Africans, risk of overall microangiopathy was − 66% and that of DR − 86%. Conclusions: An inverse association was observed between NAFL and the presence of diabetic retinopathy, cataract and ocular hypertonia. The ophthalmoprotection conferred by liver steatosis was found in Caucasians and Africans. Among the latter, hepatic steatosis was linked to lower lipoprotein(a) levels. There was no association between hepatic steatosis and prevalent macrovascular complications in neither of the two ethnic groups.
Diehl, A.M. and Day, C. (2017) Cause, Pathogenesis, and Treatment of Nonalcoholic Steatohepatitis. The New England Journal of Medicine, 377, 2063-2072. https://doi.org/10.1056/NEJMra1503519
Stefan, N., Haring, H.U. and Cusi, K. (2019) Non-Alcoholic Fatty Liver Disease: Causes, Diagnosis, Cardiometabolic Consequences, and Treatment Strategies. The Lancet Diabetes & Endocrinology, 7, 313-324. https://doi.org/10.1016/S2213-8587(18)30154-2
Targher, G., Day, C.P. and Bonora, E. (2010) Risk of Cardiovascular Disease in Patients with Nonalcoholic Fatty Liver Disease. The New England Journal of Medicine, 363, 1341-1350. https://doi.org/10.1056/NEJMra0912063
Hagstrom, H., Nasr, P., Ekstedt, M., Hammar, U., Stal, P., Askling, J., Hultcrantz, R. and Kechagias, S. (2019) Cardiovascular Risk Factors in Non-Alcoholic Fatty Liver Disease. Liver International, 39, 197-204. https://doi.org/10.1111/liv.13973
Onyekwere, C.A., Ogbega, A.O. and Balogun, B.O. (2011) Non-Alcoholic Fatty Liver Disease and the Metabolic Syndrome in an Urban Hospital Serving an Africa Community. Annals of Hepatology, 10, 119-124. https://doi.org/10.1016/S1665-2681(19)31559-5
Yu, S.S., Castillo, D.C., Courville, A.B. and Sumner, A.E. (2012) The Triglyceride Paradox in People of African Descent. Metabolic Syndrome and Related Disorders, 10, 77-82. https://doi.org/10.1089/met.2011.0108
Olusanya, T.O., Lesi, O.A., Adeyomoye, A.A. and Fasanmade, O.A. (2016) Non Alcoholic Fatty Liver Disease in a Nigerian Population with Type II Diabetes Mellitus. The Pan African Medical Journal, 24, 20. https://doi.org/10.11604/pamj.2016.24.20.8181
Sherif, Z.A., Saeed, A., Ghavimi, S., Nouraie, S.M., Laiyemo, A.O., Brim, H. and Ashktorab, H. (2016) Global Epidemiology of Nonalcoholic Fatty Liver Disease and Perspectives on US Minority Populations. Digestive Diseases and Sciences, 61, 1214-1225. https://doi.org/10.1007/s10620-016-4143-0
Bril, F., Portillo-Sanchez, P., Liu, I.C., Kalavalapalli, S., Dayton, K. and Cusi, K. (2018) Clinical and Histologic Characterization of Nonalcoholic Steatohepatitis in African American Patients. Diabetes Care, 41, 187-192. https://doi.org/10.2337/dc17-1349
Naran, N.H., Haagensen, M. and Crowther, N.J. (2018) Steatosis in South African Women: How Much and Why? PLoS ONE, 13, e0191388. https://doi.org/10.1371/journal.pone.0191388
Kneeman, J.M., Misdraji, J. and Corey, K.E. (2012) Secondary Causes of Nonalcoholic Fatty Liver Disease. Therapeutic Advances in Gastroenterology, 5, 199-207. https://doi.org/10.1177/1756283X11430859
Alberti, K.G., Eckel, R.H., Grundy, S.M., Zimmet, P.Z., Cleeman, J.I., Donato, K.A., Fruchart, J.C., James, W.P., Loria, C.M. and Smith Jr., S.C. (2009) Harmonizing the Metabolic Syndrome: A Joint Interim Statement of the International Diabetes Federation Task Force on Epidemiology and Prevention; National Heart, Lung, and Blood Institute; American Heart Association; World Heart Federation; International Atherosclerosis Society; and International Association for the Study of Obesity. Circulation, 120, 1640-1645. https://doi.org/10.1161/CIRCULATIONAHA.109.192644
Hermans, M.P., Ahn, S.A., Amoussou-Guenou, K.D. and Rousseau, M.F. (2010) Impact of Metabolic Syndrome on Microvascular Complications in Type 2 Diabetes. Diabetology & Metabolic Syndrome, 4, 150-154. https://doi.org/10.1016/j.dsx.2010.05.021
Hermans, M.P., Ahn, S.A. and Rousseau, M.F. (2017) The Mixed Benefit of Low Lipoprotein(a) in Type 2 Diabetes. Lipids in Health and Disease, 16, 171. https://doi.org/10.1186/s12944-017-0564-9
Hermans, M.P., Amoussou-Guenou, K.D., Bouenizabila, E., Sadikot, S.S., Ahn, S.A. and Rousseau, M.F. (2017) Size, Density and Cholesterol Load of HDL Predict Microangiopathy, Coronary Artery Disease and β-Cell Function in Men with T2DM. Diabetology & Metabolic Syndrome, 11, 125-131. https://doi.org/10.1016/j.dsx.2016.08.029
Hermans, M.P., Mahadeb, Y.P., Katchunga, P., Cikomola Cirhuza, J., Ahn, S.A. and Rousseau, M.F. (2014) Novel Sexual Dimorphisms of Sleep Apnea Syndrome in Diabetes. Diabetology & Metabolic Syndrome, 8, 36-44. https://doi.org/10.1016/j.dsx.2013.08.002
Hermans, M.P., Levy, J., Morris, R.J. and Turner, R.C. (1999) Comparison of Insulin Sensitivity Tests across a Range of Glucose Tolerance from Normal to Diabetes. Diabetologia, 42, 678-687. https://doi.org/10.1007/s001250051215
Hermans, M.P., Levy, J., Morris, R.J. and Turner, R.C. (1999) Comparison of Tests of Beta-Cell Function across a Range of Glucose Tolerance from Normal to Diabetes. Diabetes, 48, 1779-1786. https://doi.org/10.2337/diabetes.48.9.1779
Munoko, Th. and Hermans, M.P. (2008) Phenotypic Characterization of First Generation Maghrebian Migrants with Type 2 Diabetes: A Gender-Based Comparison with a Reference North-Caucasian Belgian Cohort. Diabetology & Metabolic Syndrome, 2, 115-124. https://doi.org/10.1016/j.dsx.2008.02.004
Dehout, F., Haumont, S., Gaham, N., Amoussou-Guenou, K.D. and Hermans, M.P. (2008) Metabolic Syndrome in Bantu Subjects with Type 2 Diabetes from Sub-Saharan Extraction: Prevalence, Gender Differences and HOMA-Hyperbolic Product. Diabetology & Metabolic Syndrome, 2, 5-11. https://doi.org/10.1016/j.dsx.2007.11.008
Targher, G., Bertolini, L., Rodella, S., Zoppini, G., Lippi, G., Day, C. and Muggeo, M. (2008) Non-Alcoholic Fatty Liver Disease Is Independently Associated with an Increased Prevalence of Chronic Kidney Disease and Proliferative/Laser-Treated Retinopathy in Type 2 Diabetic Patients. Diabetologia, 51, 444-450. https://doi.org/10.1007/s00125-007-0897-4
Lv, W.S., Sun, R.X., Gao, Y.Y., Wen, J.P., Pan, R.F., Li, L., Wang, J., Xian, Y.X., Cao, C.X. and Zheng, M. (2013) Nonalcoholic Fatty Liver Disease and Microvascular Complications in Type 2 Diabetes. World Journal of Gastroenterology, 19, 3134-3142. https://doi.org/10.3748/wjg.v19.i20.3134
Kim, B.Y., Jung, C.H., Mok, J.O., Kang, S.K. and Kim, C.H. (2014) Prevalences of Diabetic Retinopathy and Nephropathy Are Lower in Korean Type 2 Diabetic Patients with Non-Alcoholic Fatty Liver Disease. Journal of Diabetes Investigation, 5, 170-175. https://doi.org/10.1111/jdi.12139
Yan, L.H., Mu, B., Guan, Y., Liu, X., Zhao, N., Pan, D. and Wang, S.Z. (2016) Assessment of the Relationship between Non-Alcoholic Fatty Liver Disease and Diabetic Complications. Journal of Diabetes Investigation, 7, 889-894. https://doi.org/10.1111/jdi.12518
Hermans, M.P., Ahn, S.A. and Rousseau, M.F. (2011) Statin Therapy and Cataract in Type 2 Diabetes. Diabetes & Metabolism, 37, 139-143. https://doi.org/10.1016/j.diabet.2010.09.005
Hermans, M.P., Ahn, S.A. and Rousseau, M.F. (2012) The Atherogenic Dyslipidemia Ratio [Log(TG)/HDL-C] Is Associated with Residual Vascular Risk, B-Cell Function Loss and Microangiopathy in Type 2 Diabetes Females. Lipids in Health and Disease, 11, 132. https://doi.org/10.1186/1476-511X-11-132
Sacks, F.M., Hermans, M.P., Fioretto, P., Valensi, P., Davis, T., Horton, E., Wanner, C., Al-Rubeaan, K., Aronson, R., Barzon, I., Bishop, L., Bonora, E., Bunnag, P., Chuang, L.M., Deerochanawong, C., Goldenberg, R., Harshfield, B., Hernández, C., Herzlinger-Botein, S., Itoh, H., Jia, W., Jiang, Y.D., Kadowaki, T., Laranjo, N., Leiter, L., Miwa, T., Odawara, M., Ohashi, K., Ohno, A., Pan, C., Pan, J., Pedro-Botet, J., Reiner, Z., Rotella, C.M., Simo, R., Tanaka, M., Tedeschi-Reiner, E., Twum-Barima, D., Zoppini, G. and Carey, V.J. (2014) Association between Plasma Triglycerides and High-Density Lipoprotein Cholesterol and Microvascular Kidney Disease and Retinopathy in Type 2 Diabetes Mellitus: A Global Case-Control Study in 13 Countries. Circulation, 129, 999-1008. https://doi.org/10.1161/CIRCULATIONAHA.113.002529
Hammer, S.S., Beli, E., Kady, N., Wang, Q., Wood, K., Lydic, T.A., Malek, G., Saban, D.R., Wang, X.X., Hazra, S., Levi, M., Busik, J.V. and Grant, M.B. (2017) The Mechanism of Diabetic Retinopathy Pathogenesis Unifying Key Lipid Regulators, Sirtuin 1 and Liver X Receptor. EBioMedicine, 22, 181-190. https://doi.org/10.1016/j.ebiom.2017.07.008
Hammer, S.S. and Busik, J.V. (2017) The Role of Dyslipidemia in Diabetic Retinopathy. Vision Research, 139, 228-236. https://doi.org/10.1016/j.visres.2017.04.010
Zheng, W., Reem, R.E., Omarova, S., Huang, S., DiPatre, P.L., Charvet, C.D., Curcio, C.A. and Pikuleva, I.A. (2012) Spatial Distribution of the Pathways of Cholesterol Homeostasis in Human Retina. PLoS ONE, 7, e37926. https://doi.org/10.1371/journal.pone.0037926
Ducheix, S., Montagner, A., Theodorou, V., Ferrier, L. and Guillou, H. (2013) The Liver X Receptor: A Master Regulator of the Gut-Liver Axis and a Target for Non Alcoholic Fatty Liver Disease. Biochemical Pharmacology, 86, 96-105. https://doi.org/10.1016/j.bcp.2013.03.016
Xu, P., Zhai, Y. and Wang, J. (2018) The Role of PPAR and Its Cross-Talk with CAR and LXR in Obesity and Atherosclerosis. International Journal of Molecular Sciences, 19, e1260. https://doi.org/10.3390/ijms19041260
Cave, M.C., Clair, H.B., Hardesty, J.E., Falkner, K.C., Feng, W., Clark, B.J., Sidey, J., Shi, H., Aqel, B.A., McClain, C.J. and Prough, R.A. (2016) Nuclear Receptors and Nonalcoholic Fatty Liver Disease. Biochimica et Biophysica Acta, 1859, 1083-1099. https://doi.org/10.1016/j.bbagrm.2016.03.002